TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 18 years old with previously untreated AML who are not candidates for intensive remission induction therapy; relapsed/refractory AML for whom no other standard therapy is available or appropriate; or relapsed/refractory MDS who have received prior therapy with a hypomethylating agent or who are not candidates to receive a hypomethylating agent~* Histopathologically/cytologically documented primary or secondary AML, as defined by WHO criteria, or MDS, confirmed by pathology review at treating institution~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2~* Life expectancy of at least 3 months~Exclusion Criteria:~* Histological diagnosis of acute promyelocytic leukemia (FAB Type M3)~* Clinically significant central nervous system leukemia~* Treatment of the underlying hematologic condition with systemic therapy during the treatment period, including any chemotherapy, radiation or investigational therapy, within 2 weeks prior to KHK2823 administration; or immunotherapy within 30 days prior to KHK2823 administration; with the exception of hydroxyurea (Hydrea®) for treatment of hyperleukocytosis, which must be discontinued at least 24 hours prior to the first dose of KHK2823

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KHK2823 (Type: EXPERIMENTAL): single agent KHK2823 administered at selected dose levels

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tirofiban for Patients Treated With Alteplase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18~* Ischemic stroke symptom with onset ≤4.5 hours treated with IV rt-PA according with local guidelines.~* 6≤ NIHSS ≤20 before IV tPA, or NIHSS \>20 but decrease ≥ 8 after IV rt-PA.~* ≥ 4 point total NIHSS or ≥ 2 point in one NIHSS category during and after the IV rt-PA compared to immediately before worsening, an emergency CT scan should be performed to exclude intracranial hemorrhage~* Patients or their legally acceptable representative agreed to the treatment and signed the informed consent form~Exclusion Criteria:~* Patients whom the treating physician is planning to treat with mechanical thrombectomy or other endovascular procedure (e.g. Intra-arterial thrombolysis) according with local guidelines.~* Patients had used antiplatelet therapy in the past 5 days before the stroke.~* Patients had used anticoagulant therapy in the past 5 days before the stroke.~* Scheduled for surgery or interventional treatment requiring study drug cessation.~* CT scan finding of hypoattenuation involving ≥1/3 of the MCA territory.~* Any evidence of clinically significant bleeding ,or known coagulopathy.~* Renal insufficiency (creatinine clearance rate \<30ml/min)~* Hepatic dysfunction (ALT \>2 folds of Upper limit of normal value or AST\>2 folds of Upper limit of normal value).~* Pre-existing disability with ≥ mRS 2.~* Known allergic to tirofiban or other glycoprotein IIb/IIIa antagonist.~* Severe non-cerebrovascular disease with life expectancy \<3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tirofiban and alteplase (Type: EXPERIMENTAL): None
- Alteplase (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Persons with non-small cell lung cancer (NSCLC) who have undergone surgical resection, via a lobectomy, pneumonectomy, or wedge resection and currently have no evidence of disease (NED).~* Persons with head/neck squamous cell cancer who have undergone radical head and/or neck resection and who currently have NED.~* Persons with severe chronic, obstructive, pulmonary disease as evidenced by pulmonary function abnormalities: i.e. FEV1 \< 50%predicted; RV \> 200% predicted and/or DLCO \< 40% predicted.~Exclusion Criteria:~* Persons with uncontrolled hypertension (systolic pressure \>200mmHG, diastolic pressure \>120 mm HG)~* Persons with unstable angina.~* Persons with known or suspected pneumonia.~* Persons with acute bronchitis within one month of the procedure.~* Persons who have received neoadjuvant or adjuvant chemo- or radio-therapy within the past six months.~* Persons with white blood count (WBC) less than 2000 or greater than 20,000 and/or platelet count less than 50,000.~* Persons with any known bleeding dyscrasia.~* Persons who have received fluorescent photosensitizing drugs such as Photofrin within one month of the procedure.~* Persons with a known allergic reaction to topical xylocaine (lidocaine).~* Persons who have received or are on chemopreventive drugs (i.e. retinoic acid) within one month of the procedure.~* Persons who have received ionizing radiation to the chest within six months of the procedure.~* Persons who have received systemic cytotoxic chemotherapeutic agents within the past six months.~* Persons who are pregnant or nursing. All women of childbearing potential must have a negative serum pregnancy test prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: International Immune Tolerance Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe hemophilia A (FVIII level \<1%).~* A maximum historical inhibitor titer of between 5 BU and 200 BU that must be confirmed once prior to the beginning of ITI.~* The inhibitor titer should be \<10 BU at the start of ITI, confirmed once.~* The inhibitor must be present for \<24 months when ITI begins.~* Maximum age of 7 at the start of ITI.~* Willingness to comply with the protocol.~Exclusion Criteria:~* Moderate or mild hemophilia A (FVIII level \>1%).~* Spontaneous disappearance of the inhibitor prior to ITI.~* Historical maximum inhibitor titer \<5 BU or \> 200 BU before starting ITI.~* Inhibitor titer \> 10 BU at the start of ITI.~* Inhibitor present for more than 24 months before starting ITI.~* Systemic immunomodulatory drug therapy during immune tolerance e.g. corticosteroids (\< 5 days every 2 months maximum dose 2 mg/kg or 60 mg/day), azathioprine, cyclophosphamide, high-dose immunoglobulin or the use of a protein A column or plasmapheresis.~* Age \> 7 years at the start of ITI.~* Inability or unwillingness to comply with the protocol.~* Previous attempt at ITI.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Low-dose treatment (50 FVIII u/kg three times a week).
- 2 (Type: ACTIVE_COMPARATOR): High-dose treatment (200 FVIII u/kg per day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: HD5 Levels in Catheter Versus Bag Urine Specimens in Young Children for the Diagnosis of UTI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patient is between 1 to 24 months of age Patient has reported or measured fever \>38.5 degrees C (101.3 degrees F)~Exclusion Criteria:~RSV Positive at time of urine collection Flu Positive at time of urine collection Known GU abnormality Neurogenic bladder Frequent catheterizations Indwelling catheter Antibiotics in the last 7 days

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 24 Months
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of PrevenaTM on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is male or female and 18 years of age or older~* Is scheduled for elective cardiac surgery for which a median sternotomy is needed (including coronary artery bypass grafting (CABG), valvular repair or replacement with or without CABG). Elective surgery is defined as planned surgery a minimum of 24 hours before the procedure.~* Is capable of providing informed consent, which must be obtained prior to any study-related procedures~* Is willing and able to adhere to the study visit schedule and other protocol requirements.~Exclusion Criteria:~* Is pregnant~* The use of Prevena post surgery is contra indicated per investigator's discretion~* Has a systemic infection at the time of surgery: systemic infection is diagnosed on the basis of clinical signs of sepsis with or without a positive culture of an organism from the bloodstream~* Has a remote body site infection at the time of surgery (including dental, urinary or skin soft tissue infections)~* Is known to have a current nasal swab positive for methicillin-resistant staphylococcus aureus (MRSA)~* Has a known allergy or hypersensitivity to silver, or drape materials that contain acrylic adhesives~* Has a requirement for competing wound therapy and procedures.~* Any concomitant therapies (including other NPWT treatment) or procedures deviating from the clinical standard incision treatment or with investigational device at the location of the sternotomy (e.g. use of NPWT at other location of the body is allowed)~* Any other therapies or procedures that, in the opinion of the treating physician, would affect or influence postoperative wound stability or healing~* Is simultaneously participating in another interventional trial~* Requires use of liquid skin adhesives or glues during skin closure~* Is known to be serology positive for hepatitis B, hepatitis C or HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prevena™ Incision Management System (Type: EXPERIMENTAL): Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
- Conventional sterile wound dressings (Type: ACTIVE_COMPARATOR): Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hand Injected Ventriculography vs. Power Injected Left Ventriculography

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients greater than 18 years of age referred for radial coronary angiography with left ventriculography for clinical indications at the Loma Linda Heart and Surgical Hospital or the Loma Linda University Medical Center will be included in this study.~Exclusion Criteria:~* Patients with a prosthetic aortic valve~* Patients with severe aortic stenosis~* Patients with suspected left main coronary artery disease~* Patients with other contraindications to left ventriculography.~* Patients with chronic kidney disease with a baseline creatinine ≥2.0 mg/dl if not already on renal replacement therapy will also be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radial Coronary Angiography (Type: None): The subjects enrolled in this study will be adults referred for radial coronary angiography with left ventriculography for clinical indications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cerebrovascular accident diagnosed 3-18 months before enrollment. Treated at th Neurologic Rehabilitation Center of Clalit Health Services in Kiryat Byalik, Israel.~Living in the community (in their homes). Are capable of basic communication in Hebrew.~Exclusion Criteria:~Moderate-severe stroke (National Institutes of Health Stroke Scale (NIHSS) score ≤ 16).~Moderate-Severe Cognitive impairment (Montreal Cognitive Assessment (MOCA) - total score ≤ 16). Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Self-Management group-intervention (Type: EXPERIMENTAL): Participants will receive Self-Management group-intervention + Standard Care
- Standard Care (Type: ACTIVE_COMPARATOR): Participants will receive Standard Care only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antiretroviral Improvement Among Medicaid Enrollees

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Current enrollment in Virginia Medicaid;~* Continuous Virginia Medicaid enrollment for the preceding 9 or more months;~* Current age 19-64 years;~* Identified as living with HIV according to an HIV case identification algorithm;~* Non-dual eligible for Medicare;~* History of ART prescription claim(s) within the past 12 months;~* Prior ART prescription claim, with claims for the most recent ART prescription refill(s) \>30 days late.~Exclusion criteria:~* Record of non-Medicaid health insurance or other health care service payer in past 3 months;~* New prescription claim(s) within 30 days for within-class ART drug(s) not previously prescribed;~* Service claim(s) for resistance testing and other ART prescription claim(s) within 30 days of most recent late ART prescription(s) for ART drug(s) not previously prescribed;~* Enrollee's linked HIV provider practices at a healthcare facility offering PositiveLinks;~* No record in the Virginia HIV surveillance data;~* Non-English speaking.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: OTHER): Usual Care participants will receive standard state-level care for missing ART prescription refill(s) for Virginia Medicaid enrollees with HIV.
- AIMS program - patient (Type: EXPERIMENTAL): Participants will receive patient-level support. Support will come from the participant's provider, pharmacy, managed-care organization or the community.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extubation Failure Prevention in High Risk Patients by High-flow Conditioned Oxygen Therapy vs. Standard Oxygen Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients mechanically ventilated for \> 48 hours and at least one of the following:~* \>65 years~* cardiac failure as the primary indication of mechanical ventilation~* Chronic Obstructive Pulmonary Disease~* Severity score (APACHE II \>12 points) the extubation day~* Body Mass Index \>30~* inability to manage respiratory secretions~* 1 failed spontaneous breathing trial~* 1 comorbidity~* 7 days under mechanical ventilation~Exclusion Criteria:~* \<18 years~* tracheotomized patients~* recent facial or cervical trauma/surgery~* active gastro-intestinal bleeding~* lack of cooperation~* patients with any failed spontaneous breathing trial because of hypercapnia development.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- High Flow Conditioned Oxygen Therapy (Type: EXPERIMENTAL): Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
- Standard Oxygen Therapy (Type: ACTIVE_COMPARATOR): The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patients with metastatic prostate adenocarcinoma, who have failed initial hormone therapy and who have had progression after at least one chemotherapy regimen that included docetaxel. Patients on antiandrogens must have progression after withdrawal of the antiandrogen for 4 weeks (flutamide) or 6 weeks (bicalutamide).~* PSA ≥ 10 ng/ml.~* Patients who have received LHRH agonist therapy for \> 1 month must maintain agonist therapy while on-study. Patients who have not received agonist therapy or received \< 1 month of therapy, may not begin or continue agonist therapy while on-study.~* Age \>18 years and an estimated life expectancy of at least 4 months.~* ECOG performance status ≤ 2 (see Appendix B).~* Full recovery from the effects of any prior surgery or radiation therapy within 4 weeks of study entry.~* Serum creatinine ≤ 1.5 x ULN~* Total bilirubin \< ULN~* Transaminases (SGOT and/or SGPT) ≤ 2 X institutional upper limit.~* Capacity to give informed, written consent.~Exclusion Criteria~* Any coexisting medical condition precluding full compliance with the study.~* Any history of deep venous thrombosis (DVT) or pulmonary embolus. Patients with a DVT on anticoagulants for ≥ 6 months will be eligible.~* Known CNS metastasis.~* The discontinuation of flutamide or bicalutamide \< 4 or 6 weeks respectively.~* History of severe cardiovascular disease (AHA class III or IV; see Appendix C), uncontrolled CHF or life threatening cardiac dysrhythmia in the past 6 months.~* Herbal supplements may not be used while on-study and patients must have discontinued use for ≥ 1 week before entering on-study.~* Patients with a known hypersensitivity to estrogen.~* Triglyceride \> 200 mg/dl.~* Prior estramustine.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transdermal estradiol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Shared Decision Making in Older Adults With Distal Radius Fractures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Distal radius fracture within the past 2 weeks~* Initial appointment seeing Attending~* Age 65+~Exclusion Criteria:~* Non english speaker~* Dementia or other mental limitation preventing ability to complete survey~* Other traumatic injuries in extremity that would affect surgical decision

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): This group will not be exposed to the decision aid. Patients will complete the same surveys, and will be followed for the same length of time.
- Decision Aid (Type: EXPERIMENTAL): This group will be exposed to the decision aid before the patients appointment with the surgeon. Patients will also complete the same outcome surveys, and will be followed for the same length of time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval